OVID THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.23 USD | +3.86% |
|
-2.71% | +0.31% |
| 14/05 | Earnings Flash (OVID) OVID THERAPEUTICS Posts Q1 Revenue $148,000 | MT |
| 14/05 | Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechJeremy Levin (Executives)Okay. Are we ready? Perfect. So ladies and gentlemen,...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
Calendar
06/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.23
USD
Average target price
7.562
USD
Spread / Average Target
+134.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.31% | 23Cr | |
| +9.99% | 12TCr | |
| +12.01% | 11TCr | |
| -3.07% | 2.47TCr | |
| -0.64% | 2.2TCr | |
| -4.69% | 1.93TCr | |
| -6.90% | 1.76TCr | |
| -39.36% | 1.73TCr | |
| +5.82% | 1.4TCr | |
| +33.05% | 1.21TCr |
- Stock Market
- Equities
- OVID Stock
- News Ovid Therapeutics Inc.
- Transcript : Ovid Therapeutics Inc. - Special Call
